PCM
CBAY

Penserra Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Penserra Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,580
Closed -$5K – 1598
2021
Q3 		$5K Buy
1,580
+10
+0.6% +$39 ﹤0.01% 1414
2021
Q2 		$6K Sell
1,570
-25
-2% -$111 ﹤0.01% 1313
2021
Q1 		$7K Buy
1,595
+15
+0.9% +$81 ﹤0.01% 1066
2020
Q4 		$9K Buy
1,580
+994
+170% +$7.52K ﹤0.01% 940
2020
Q3 		$4K Buy
+586
New +$3.13K ﹤0.01% 875

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

Penserra Capital Management's CBAY Position: Q4 2021 in Review

Penserra Capital Management sold out of Cymabay Therapeutics (CBAY) in Q4 2021, closing a stake of 1,580 shares — an estimated $5K sold.

Penserra Capital Management first reported a position in CBAY in Q3 2020 and held it in 5 quarters. The position peaked at $9K in Q4 2020. 113 funds tracked by Wall St. Rank hold CBAY as of Q4 2021.

  • Penserra Capital Management reported no remaining Cymabay Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 1,580 Cymabay Therapeutics shares in Q4 2021, an estimated $5K.
  • Penserra Capital Management first reported a position in Cymabay Therapeutics in Q3 2020 and held it in 5 quarters.
  • Penserra Capital Management's Cymabay Therapeutics position peaked at $9K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.